ArQule Company Profile (NASDAQ:ARQL)

About ArQule (NASDAQ:ARQL)

ArQule logoArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ARQL
  • CUSIP: 04269E10
  • Web: www.arqule.com
Capitalization:
  • Market Cap: $81.85 million
  • Outstanding Shares: 71,171,000
Average Prices:
  • 50 Day Moving Avg: $1.09
  • 200 Day Moving Avg: $1.13
  • 52 Week Range: $0.92 - $1.82
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.80
  • P/E Growth: -0.53
Sales & Book Value:
  • Annual Revenue: $2.41 million
  • Price / Sales: 33.08
  • Book Value: $0.14 per share
  • Price / Book: 8.00
Profitability:
  • EBIDTA: ($26,760,000.00)
  • Net Margins: -482.44%
  • Return on Equity: -135.68%
  • Return on Assets: -77.68%
Debt:
  • Debt-to-Equity Ratio: 1.43%
  • Current Ratio: 4.33%
  • Quick Ratio: 4.33%
Misc:
  • Average Volume: 127,527 shs.
  • Beta: 1.51
  • Short Ratio: 10.48
 

Frequently Asked Questions for ArQule (NASDAQ:ARQL)

What is ArQule's stock symbol?

ArQule trades on the NASDAQ under the ticker symbol "ARQL."

How were ArQule's earnings last quarter?

ArQule, Inc. (NASDAQ:ARQL) issued its quarterly earnings data on Friday, August, 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. ArQule had a negative return on equity of 135.68% and a negative net margin of 482.44%. During the same period last year, the business posted ($0.07) earnings per share. View ArQule's Earnings History.

When will ArQule make its next earnings announcement?

ArQule is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for ArQule.

Who are some of ArQule's key competitors?

Who are ArQule's key executives?

ArQule's management team includes the folowing people:

  • Patrick J. Zenner, Independent Chairman of the Board
  • Peter S. Lawrence, President, Chief Operating Officer
  • Paolo Pucci, Chief Executive Officer, Director
  • Robert J. Weiskopf, Chief Financial Officer, Treasurer
  • Brian Schwartz M.D., Chief Medical Officer
  • Timothy C. Barabe, Independent Director
  • Susan L. Kelley M.D., Independent Director
  • Ronald M. Lindsay Ph.D., Independent Director
  • Michael D. Loberg Ph.D., Independent Director
  • William G. Messenger D. Min., Independent Director

Who owns ArQule stock?

ArQule's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include First Eagle Investment Management LLC (16.65%), Vanguard Group Inc. (3.63%), NEA Management Company LLC (3.54%), DAFNA Capital Management LLC (1.10%), California Public Employees Retirement System (0.32%) and Northern Trust Corp (0.22%). Company insiders that own ArQule stock include Michael D Loberg, Paolo Pucci and Patrick J Zenner. View Institutional Ownership Trends for ArQule.

Who sold ArQule stock? Who is selling ArQule stock?

ArQule's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and DAFNA Capital Management LLC. View Insider Buying and Selling for ArQule.

Who bought ArQule stock? Who is buying ArQule stock?

ArQule's stock was bought by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC and Northern Trust Corp. Company insiders that have bought ArQule stock in the last two years include Michael D Loberg, Paolo Pucci and Patrick J Zenner. View Insider Buying and Selling for ArQule.

How do I buy ArQule stock?

Shares of ArQule can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ArQule's stock price today?

One share of ArQule stock can currently be purchased for approximately $1.12.


MarketBeat Community Rating for ArQule (NASDAQ ARQL)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  88 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  187
MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ArQule (NASDAQ:ARQL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for ArQule (NASDAQ:ARQL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/1/2016Leerink SwannLower Price TargetMarket Perform$3.00 -> $2.50N/AView Rating Details
12/27/2015Royal Bank Of CanadaUpgradeBuyN/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for ArQule (NASDAQ:ARQL)
Earnings by Quarter for ArQule (NASDAQ:ARQL)
Earnings History by Quarter for ArQule (NASDAQ ARQL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.11)N/AView Earnings Details
8/4/2017Q2 2017($0.11)($0.10)ViewN/AView Earnings Details
5/3/2017Q1 2017($0.11)($0.11)ViewListenView Earnings Details
3/7/2017Q4 2016($0.10)($0.10)$1.20 million$1.19 millionViewListenView Earnings Details
11/7/2016Q316($0.09)($0.08)$1.10 million$1.22 millionViewListenView Earnings Details
8/3/2016Q216($0.08)($0.07)$1.13 million$1.07 millionViewN/AView Earnings Details
5/4/2016Q116($0.07)($0.08)$1.63 million$1.28 millionViewN/AView Earnings Details
2/29/2016Q415($0.06)($0.05)$2.40 million$2.80 millionViewListenView Earnings Details
11/4/2015Q315($0.08)($0.04)$2.60 million$2.65 millionViewN/AView Earnings Details
8/5/2015Q215($0.08)($0.06)$2.50 million$3.04 millionViewN/AView Earnings Details
5/6/2015Q115($0.08)($0.07)$1.98 million$2.79 millionViewN/AView Earnings Details
3/4/2015Q414($0.13)($0.06)$1.90 million$3.02 millionViewN/AView Earnings Details
11/10/2014Q314($0.13)($0.10)$2.20 million$2.66 millionViewN/AView Earnings Details
8/5/2014Q214($0.13)($0.10)$2.43 million$2.90 millionViewN/AView Earnings Details
5/7/2014Q114($0.11)($0.11)$2.29 million$2.67 millionViewN/AView Earnings Details
3/5/2014Q413($0.13)($0.10)$2.27 million$2.28 millionViewN/AView Earnings Details
10/31/2013Q313($0.13)($0.10)$2.77 million$3.50 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.12)($0.11)$3.84 million$4.44 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.11)($0.09)$3.78 million$5.66 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.13)($0.09)$5.17 million$5.14 millionViewN/AView Earnings Details
11/1/2012($0.07)($0.01)ViewN/AView Earnings Details
8/2/2012($0.07)($0.01)ViewN/AView Earnings Details
5/3/2012($0.07)($0.08)ViewN/AView Earnings Details
3/1/2012($0.09)$0.07ViewN/AView Earnings Details
11/10/2011($0.23)($0.04)ViewN/AView Earnings Details
8/4/2011($0.19)($0.20)ViewN/AView Earnings Details
5/5/2011($0.08)($0.03)ViewN/AView Earnings Details
3/1/2011($0.15)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ArQule (NASDAQ:ARQL)
2017 EPS Consensus Estimate: ($0.45)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.10)($0.10)($0.10)
Q2 20171($0.11)($0.11)($0.11)
Q3 20171($0.12)($0.12)($0.12)
Q4 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ArQule (NASDAQ:ARQL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ArQule (NASDAQ:ARQL)
Insider Ownership Percentage: 9.00%
Institutional Ownership Percentage: 60.95%
Insider Trades by Quarter for ArQule (NASDAQ:ARQL)
Institutional Ownership by Quarter for ArQule (NASDAQ:ARQL)
Insider Trades by Quarter for ArQule (NASDAQ:ARQL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/7/2017Paolo PucciCEOBuy1,101$1.15$1,266.15View SEC Filing  
9/6/2017Paolo PucciCEOBuy16,397$1.15$18,856.55View SEC Filing  
9/5/2017Paolo PucciCEOBuy19,156$1.14$21,837.84View SEC Filing  
8/29/2017Paolo PucciCEOBuy300$1.05$315.00View SEC Filing  
8/28/2017Paolo PucciCEOBuy2,970$1.05$3,118.50View SEC Filing  
8/25/2017Paolo PucciInsiderBuy9,492$1.05$9,966.60View SEC Filing  
12/17/2015Michael D LobergDirectorBuy3,719$2.16$8,033.04View SEC Filing  
12/16/2015Michael D LobergDirectorBuy1,231$2.14$2,634.34View SEC Filing  
12/15/2015Paolo PucciCEOBuy1,283$2.16$2,771.28View SEC Filing  
12/11/2015Paolo PucciCEOBuy1,108$2.10$2,326.80View SEC Filing  
12/11/2015Patrick J ZennerDirectorBuy2,300$2.15$4,945.00View SEC Filing  
12/10/2015Paolo PucciCEOBuy7,609$2.10$15,978.90View SEC Filing  
3/11/2015Patrick J ZennerDirectorBuy10,625$2.32$24,650.00View SEC Filing  
11/20/2014Paolo PucciCEOBuy5,000$1.26$6,300.00View SEC Filing  
11/14/2014Patrick J ZennerDirectorBuy20,830$1.20$24,996.00View SEC Filing  
11/13/2014Susan L KelleyDirectorBuy50,000$1.20$60,000.00View SEC Filing  
9/4/2014Paolo PucciCEOBuy5,000$1.31$6,550.00View SEC Filing  
5/23/2014Paolo PucciCEOBuy5,000$1.40$7,000.00View SEC Filing  
5/20/2014Paolo PucciCEOBuy5,000$1.42$7,100.00View SEC Filing  
3/17/2014Patrick ZennerDirectorBuy4,715$2.12$9,995.80View SEC Filing  
3/13/2014Paolo PucciCEOBuy10,000$2.10$21,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ArQule (NASDAQ:ARQL)
Latest Headlines for ArQule (NASDAQ:ARQL)
Source:
DateHeadline
finance.yahoo.com logoArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017
finance.yahoo.com - September 19 at 4:03 PM
americanbankingnews.com logoArQule, Inc. (ARQL) Expected to Announce Earnings of -$0.12 Per Share
www.americanbankingnews.com - September 18 at 4:28 PM
americanbankingnews.com logoArQule, Inc. (ARQL) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - September 15 at 4:22 PM
americanbankingnews.com logoArQule, Inc. (ARQL) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - September 14 at 4:50 PM
americanbankingnews.com logoArQule, Inc. (ARQL) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - September 8 at 5:02 PM
americanbankingnews.com logoInsider Buying: ArQule, Inc. (ARQL) CEO Acquires 16,397 Shares of Stock
www.americanbankingnews.com - September 7 at 1:46 PM
americanbankingnews.com logoZacks Investment Research Lowers ArQule, Inc. (ARQL) to Hold
www.americanbankingnews.com - September 6 at 8:28 PM
americanbankingnews.com logoArQule, Inc. (ARQL) CEO Paolo Pucci Acquires 19,156 Shares
www.americanbankingnews.com - September 6 at 1:38 PM
americanbankingnews.com logoValuEngine Downgrades ArQule, Inc. (ARQL) to Strong Sell
www.americanbankingnews.com - September 3 at 10:10 PM
americanbankingnews.com logoArQule, Inc. (ARQL) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - August 23 at 4:46 PM
americanbankingnews.com logoArQule, Inc. (ARQL) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - August 18 at 6:58 PM
americanbankingnews.com logoArQule, Inc. (NASDAQ:ARQL) to Post FY2017 Earnings of ($0.44) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - August 10 at 1:50 PM
finance.yahoo.com logoEdited Transcript of ARQL earnings conference call or presentation 4-Aug-17 1:00pm GMT
finance.yahoo.com - August 4 at 9:46 PM
seekingalpha.com logoArQule's (ARQL) CEO Paolo Pucci on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 4 at 4:23 PM
finance.yahoo.com logoArQule Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 4 at 4:23 PM
finance.yahoo.com logoArQule reports 2Q loss
finance.yahoo.com - August 4 at 4:23 PM
americanbankingnews.com logoArQule, Inc. (ARQL) Announces Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 4 at 3:33 PM
americanbankingnews.com logoArQule, Inc. (ARQL) Expected to Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - July 25 at 12:25 PM
americanbankingnews.com logoArQule, Inc. (NASDAQ:ARQL) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - July 25 at 7:10 AM
finance.yahoo.com logoArQule To Report Second Quarter 2017 Financial Results On August 4, 2017
finance.yahoo.com - July 21 at 5:28 PM
rttnews.com logoArQule: First Patient Dosed In ARQ 531 Phase 1 Trial For B-cell Malignancies
www.rttnews.com - July 12 at 1:40 AM
finance.yahoo.com logoArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies
finance.yahoo.com - July 11 at 3:38 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ArQule, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - June 26 at 4:08 PM
streetinsider.com logoArQule (ARQL) Presents Preclinical Data for BTK Inhibitor, ARQ 531, at EHA
www.streetinsider.com - June 24 at 8:48 PM
finance.yahoo.com logoArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)
finance.yahoo.com - June 23 at 4:15 PM
finance.yahoo.com logoArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases
finance.yahoo.com - June 7 at 3:50 PM
americanbankingnews.com logo Analysts Expect ArQule, Inc. (ARQL) to Announce -$0.11 EPS
www.americanbankingnews.com - June 5 at 7:37 AM
finance.yahoo.com logoArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - June 3 at 3:40 PM
finance.yahoo.com logoArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - June 3 at 3:40 PM
baystreet.ca logoArQule Stock Up 28% on Lab Data for B-Cell Lymphoma Drug
www.baystreet.ca - May 19 at 9:27 AM
finance.yahoo.com logoArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)
finance.yahoo.com - May 18 at 12:06 PM
finance.yahoo.com logoArQule to Present Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 17 at 8:40 PM
americanbankingnews.com logoArQule, Inc. (ARQL) Short Interest Update
www.americanbankingnews.com - May 15 at 8:48 AM
americanbankingnews.com logo-$0.11 EPS Expected for ArQule, Inc. (ARQL) This Quarter
www.americanbankingnews.com - May 9 at 6:16 PM
americanbankingnews.com logoLeerink Swann Brokers Cut Earnings Estimates for ArQule, Inc. (ARQL)
www.americanbankingnews.com - May 8 at 8:26 AM
americanbankingnews.com logoArQule, Inc. (ARQL) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 4 at 7:06 PM
finance.yahoo.com logoEdited Transcript of ARQL earnings conference call or presentation 3-May-17 1:00pm GMT
finance.yahoo.com - May 4 at 1:47 AM
americanbankingnews.com logoArQule, Inc. (ARQL) Issues Earnings Results, Meets Expectations
www.americanbankingnews.com - May 3 at 12:33 PM
finance.yahoo.com logoArqule Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 9:55 AM
finance.yahoo.com logoArQule reports 1Q loss
finance.yahoo.com - May 3 at 9:55 AM
finance.yahoo.com logoInvestor Network: ArQule, Inc. to Host Earnings Call
finance.yahoo.com - May 3 at 9:55 AM
americanbankingnews.com logoArQule (ARQL) Earns Daily Media Impact Rating of 0.13
www.americanbankingnews.com - May 2 at 8:16 AM
americanbankingnews.com logoArQule, Inc. (ARQL) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - May 1 at 11:56 AM
americanbankingnews.com logoArQule (ARQL) Receiving Somewhat Favorable News Coverage, Report Shows
www.americanbankingnews.com - April 27 at 4:38 PM
finance.yahoo.com logoArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531
finance.yahoo.com - April 26 at 9:10 AM
americanbankingnews.com logoArQule (ARQL) Earning Somewhat Positive Press Coverage, Report Finds
www.americanbankingnews.com - April 20 at 2:42 PM
finance.yahoo.com logoArQule To Report First Quarter 2017 Financial Results On May 3, 2017
finance.yahoo.com - April 19 at 9:15 AM
americanbankingnews.com logo-$0.10 EPS Expected for ArQule, Inc. (ARQL) This Quarter
www.americanbankingnews.com - April 18 at 10:21 PM
americanbankingnews.com logoSomewhat Favorable Media Coverage Somewhat Likely to Impact ArQule (ARQL) Stock Price
www.americanbankingnews.com - April 17 at 12:07 PM
americanbankingnews.com logoSomewhat Critical Press Coverage Somewhat Likely to Effect ArQule (ARQL) Share Price
www.americanbankingnews.com - April 14 at 7:58 AM

Social

Chart

ArQule (ARQL) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff